Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Rating) – William Blair lowered their Q2 2023 earnings estimates for shares of Poseida Therapeutics in a research note issued on Tuesday, May 9th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($0.49) per share for the quarter, down from their prior forecast […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and Poseida Therapeutics (NASDAQ:PSTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Institutional and Insider Ownership 46.7% of Poseida Therapeutics shares […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and Poseida Therapeutics (NASDAQ:PSTX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Volatility & Risk Fate Therapeutics has a beta of […]
Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Rating) – Investment analysts at William Blair issued their Q1 2023 earnings estimates for Poseida Therapeutics in a research report issued on Wednesday, March 22nd. William Blair analyst S. Corwin expects that the company will earn ($0.24) per share for the quarter. William Blair currently has a “Outperform” rating […]
Takeda Pharmaceutical will apply Poseida Therapeutics’ technologies to develop up to eight gene therapies including a Hemophilia A candidate under development by Poseida, through a collaboration that could generate more than $3.6 billion for the San Diego cell and gene therapy developer.